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Abstract 
Head and neck squamous cell carcinoma (HNSCC) is one of the most common types of 
human cancer.  Typically HNSCC cells show persistent invasion that frequently leads to local 
recurrence and distant lymphatic metastasis.  However, molecular mechanisms associated 
with invasion and metastasis of HNSCC remain poorly understood.  Here we identified 
Periostin as an invasion promoting factor in HNSCC by comparing the gene expression 
profiles between parent HNSCC cells and a highly invasive clone.  Indeed, Periostin 
overexpression promoted the invasion and anchorage independent growth both in vitro and in 
vivo in HNSCC cells.  Moreover, Periostin overexpressing cells spontaneously metastasized 
to cervical lymph nodes and to the lung through their aggressive invasiveness in an orthotopic 
mouse model of HNSCC.  Interestingly, Periostin was highly expressed in HNSCCs in 
comparison with normal tissues, and the level of Periostin expression was well correlated with 
the invasiveness of HNSCC cases.  In summary, these findings suggest that Periostin plays 
an important role for invasion and anchorage independent growth in the metastatic process of 
HNSCC.
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Introduction 
Head and neck squamous cell carcinoma (HNSCC) is one of the most common types of 
human cancer, with an annual incidence of more than 500,000 cases worldwide (1).  
HNSCC is associated with severe disease- and treatment-related morbidity and has a 5-year 
survival rate of approximately 50%; this rate has not improved in more than 2 decades (2).  
Review of the literature indicates that the most important factor for the high mortality rate is 
the advanced stage of the disease at the time of diagnosis and treatment.  In the prognosis 
of HNSCC, the extent of lymph node metastasis is a major determinant.  Like most epithelial 
cancers, HNSCC develops through the accumulation of multiple genetic and epigenetic 
alterations in a multistep process.  Recent molecular studies have advanced our 
understanding of the disease and provided a rationale to develop novel strategies for early 
detection, classification, prevention and treatment.  Attempts to identify the genes involved in 
the metastasis is pivotal for the early prediction of HNSCC behavior.  However, the identity 
and time of onset of the alterations that endow cancer cells with these metastatic functions 
are largely unknown.  The process of metastasis consists of sequential and selective steps 
including proliferation, induction of angiogenesis, detachment, motility, invasion into 
circulation, aggregation and survival in the circulation, cell arrest in distant capillary beds and 
extravasation into organ parenchyma (3).  The development of a metastasis depends on 
interplay between host factors and intrinsic characteristics of cancer cells, and the metastatic 
lesion represents the end point of many destructive events that only a few cells can survive 
(4).  Moreover, neoplasms contain a variety of subpopulations of cells with differing 
metastatic potential, and the possible existence of highly metastatic clones may exist within a 
primary tumor (4).  Indeed, we previously isolated highly invasive clones from parent HNSCC 
cell line by using an in vitro invasion assay method (5). 
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Here we compared the transcriptional profile of parent cells and a highly invasive clone 
by microarray analysis in order to identify genes that differ in their expression.  We identified 
Periostin (osteoblast specific factor 2 (fasciclin I-like)) as the gene demonstrating the highest 
fold change expression in the invasive clone.  Periostin is a secreted protein, which was 
originally identified from osteoblasts (6, 7).  In the present study, we demonstrated that 
Periostin was involved in the invasion and anchorage independent growth in HNSCC. 
Materials and Methods 
Gene array analysis.  The Amersham CodeLink system using the UniSet Human I 
Expression Bioarray, containing 10458 genes probes, was used to compare the transcription 
profiles between parent cells and high invasive clone.  This array contains a broad range of 
genes derived from publicly available, well-annotated mRNA sequences.  The CodeLink 
array is unique in being capable of detecting minimal differences in gene expression, as low 
as 1.3-fold with 95% confidence, because of the novel three-dimensional aqueous gel matrix, 
which the empirically tested 30-mer oligonucleotides are deposited on (8).  This substantially 
reduces background, enhances sensitivity, and allows for the detection and quantification of 
subtle regulatory relationships among genes in parent HNSCC cells and highly invasive clone. 
Total RNA was isolated from cultures of confluent cells using the RNeasy Mini Kit (Qiagen) 
according to the manufacture’s instructions.  Preparations were quantified and their purity 
was determined by standard spectrophometric methods.  Data were expressed as the 
average differences between the perfect match and mismatch probes for the Periostin gene 
(Supplemental data 1).   
Total RNA from 41 primary HNSCC and 13 normal tissues was labeled and hybridized 
to Affymetrix U133A Gene Chips as previously reported (9).  To explore the genes that are 
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coordinately expressed with Periostin in HNSCC tumors, we performed a similarity search 
using a Pearson correlation metric as implemented in tGeneData Analyst Pro 1.0 software 
(Supplemental data 2).   
Cell culture.  MSCC-1 and MSCC-Inv1 cells were previously established in our laboratory (5, 
10).  These cells were maintained in Keratinocyte-SFM (Invitrogen) under a condition of 5 % 
CO2 in air at 37 ˚C.  Other HNSCC cell lines HSC2, HSC3 and Ca9-22 were provided by 
Japanese Collection of Research Bioresources Cell Bank.  They were maintained in RPMI-
1640 (Nissui Pharmaceutical Co., Tokyo, Japan) supplemented with 10 % heat-inactivated FBS 
(Invitrogen) and 100 U/ml penicillin-streptomycin (Gibco) under conditions of 5 % CO2 in air at 
37 ˚C.  For growth assay, cells were plated onto 24 well plates (Falcon), and trypsinized cells 
counted by Cell Counter (Coulter Z1). 
RT-PCR.  Total RNA was isolated from cultures of confluent cells using the RNeasy Mini Kit 
(Qiagen).  Preparations were quantified and their purity was determined by standard 
spectrophometric methods.  cDNA was synthesized from 1 !µg total RNA according to the 
ReverTra Dash (Toyobo Biochemicals, Tokyo, Japan).  Primer sequences included the 
following; human Periostin, 5’-gatggagtgcctgtggaaat-3’ (forward) and 5’-aacttcctcacgggtgtgtc-
3’ (reverse) (product size, 239bp); human GAPDH, 5’-tccaccaccctgttgctgta-3’ (forward) and 
5’-accacagtccatgccatcac-3’ (reverse) (product size, 450bp).  Aliquots of total cDNA were 
amplified with 1.25 U of rTaq-DNA polymerase (Qiagen), and amplifications were performed 
in a PC701 thermal cycler (Astec, Fukuoka, Japan) for 30-35 cycles after an initial 30 sec 
denaturation at 94 ˚C, annealed for 30 sec at 60 ˚C, and extended for 1 min at 72 ˚C in all 
primers. The amplification reaction products were resolved on 1.5% agarose/TAE gels 
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(Nacalai tesque, Inc., Kyoto, Japan), electrophoresed at 100 mV, and visualized by ethidium-
bromide staining. 
Western blot analysis.  Western blotting was carried out as we described previously (11).  
A polyclonal anti-Periostin antibody was generated by immunizing the rabbits with specific 
peptides (EGEPEFRLIKEGETC) for Periostin and purified through an affinity column.  An 
anti-His polyclonal antibody (Cell Signaling Technology Inc.) and ß-actin monoclonal antibody 
(Sigma) were also used.  Thirty µg of protein was subjected to 10 % polyacrylamide gel 
electrophoresis followed by electroblotting onto a nitrocellulose filter.  For detection of the 
immunocomplex, the ECL western blotting detection system (Amersham) was used 
Generation of Periostin-overexpressing HNSCC cells.  A Periostin expression plasmid, 
pcDNA3.1 encoding a hexa-histidine tagged Periostin cDNA, was kindly provided by Dr. X-F. 
Wang (Duke University).  The periostin/pcDNA3.1 plasmid or the vector alone was 
introduced into HSC2 and HSC3 cells, and the stable clones were obtained by G418 selection 
(500 µg/ml, Gibco) in the culture medium.  Cell transfections were performed using FuGENE 
6 (Roche) according to the manufacture’s instruction.  Four Periostin-expressing clones and 
one control clones of each cells were chosen for the subsequent experiments. 
In vitro invasion assay.  In vitro invasion assay was performed as described previously (5). 
Briefly, invasion was measured by use of a 24 well cell culture insert with 8 mm pores (3097, 
Falcon, Becton Dickinson, Franklin Lakes, NJ).  The filter was coated with 20 µg of EHS 
extract (Iwaki Garasu, Tokyo, Japan), which was reconstituted basement membrane 
substance.  The lower compartment contained 0.5 ml of serum-free medium.  After 
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trypsinization, 1.5 x 105 cells were resuspended in 100 µl of serum-free medium and placed in 
the upper compartment of the cell culture insert for 6-24 hours.  Cells were placed in the upper 
compartment of the cell culture insert for 6-24 hours.  For invasiveness after Periostin siRNA 
treatment, we used 50 µg of EHS extract in this experiments, because MSCC-Inv1 cells have a 
high invasive activity.  After incubation, we collected the penetrating cells onto the lower side 
of the filter to isolate highly invasive clones by the method of Kalebic et al. with minor 
modification (12).  To examine the invasiveness, cells were fixed with formalin and stained 
with hematoxylin and eosin.  The invasiveness of the cells was determined by counting of the 
penetrating cells onto the lower side of the filter through the pores under a microscope at x100 
magnification.  We assayed 3 times and randomly selected 3 fields were counted for each 
assay. 
Generation of recombinant Periostin.  Full-length human Periostin cDNA was subcloned 
into pIZ/V5-His vector (Invitrogen).  pIZ/V5-His vector containing Periostin was transfected 
into High-Five insect cells by using Cellfectin reagent (Invitrogen).  Stable clones were 
obtained by Zeocin selection in the culture medium.  A Ni-nitrilotriacetic acid column was 
used to purify recombinant Periostin according to the manufacturer's instructions (Invitrogen). 
Silencing by Small Interfering RNA.  Stealth siRNA (Oligo ID, HSS116398, Invitrogen) is a 
25-bp duplex oligoribonucleotide with a sense strand corresponding to nucleotides 62-86 of the
reported human Periostin mRNA sequence. The sense sequence of HSS116398 is 5'-
CCCUAUAAACGCCAACAAUCAUUAU-3'.  MSCC-Inv1 cells were transfected by 150 pmol of 
siRNA in 1 ml of OPTI-MEM per the instruction of the manufacturer.  Following siRNAs 
treatment (48 h), MSCC-Inv1 cells were used for in vitro invasion assay as described above.  
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A scrambled sequence that does not show significant homology to rat, mouse or human gene 
sequences was used as a control. 
Cell adhesion assay.  Flat-bottomed 96-well ELISA plates (Costar) were incubated overnight 
at 4°C with 10 "g/ml of Periostin protein in the presence of anti-!vß3 or anti-!vß5 integrin 
antibody (10 "g/ml) and blocked for 1 hour at room temperature with PBS containing 2% 
bovine serum albumin.  Cells were suspended in medium at a density of 3 x 105 cells/ml, and 
0.1 ml of the cell suspension was added to each well of the coated plates.  After incubation for 
1 hour at 37°C, unattached cells were removed by rinsing with PBS.  Attached cells were then 
trypsinized and counted by Cell Counter. 
Soft-Agar Colony Formation Assay.  Assays of colony formation in soft agar were 
performed using standard methods.  Briefly, 4 ml underlayers consisting of 0.5 % agar 
medium with 20 % FBS were prepared in 60 mm dishes.  Periostin overexpressing cells and 
control cells were trypsinized, centrifuged, and resuspended in 0.2 % agar medium with 20 % 
FBS.  1 x 104 cells were then plated onto the previously prepared underlayers.  The cells 
were kept wet by adding a small amount of RPMI-1640 medium with 10 % FBS.  The cells 
were incubated at 37 °C in a humidified 5% CO2 atmosphere for 3 weeks.  Then, colonies 
were photographed and counted. 
Xenograft assays in nude mice.  To examine whether Periostin expression in HNSCC cells 
affects the anchorage independent growth in vivo, Periostin-overexpressing HSC2 cells (1 # 
107 in 500 "l of Hanks’ balanced salt solution) were injected s.c. into multiple sites in athymic 
(nude) mice.  The control groups were injected with the same number of vector-transfected 
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HSC2 cells.  The protocol of the experiment was approved by the Committee of Research 
Facilities for Laboratory Animal Science, Hiroshima University.  The animals were monitored 
for tumor formation every week and sacrificed 1 month later.  Tumor length (L) and width (W) 
were measured at the end of the experiment, and tumor volume was calculated by the 
formula of (L x W2)/2. 
Orthotopic implantation.  Periostin-overexpressing and control HSC2 cells (5 # 105 in 50 "l 
of Hanks’ balanced salt solution) were injected into the tongue of male athymic (nude) mice.  
The animals were monitored for tumor formation every 3 day and sacrificed 2 weeks later.  
Tongue tumors, cervical lymph nodes and lungs were removed and fixed in 4 % formalin.  
Specimens were embedded in paraffin, cut into 4 "m-thick sections and stained with 
hematoxylin and eosin.  They were histologically evaluated for diagnosis, regional lymph 
node metastasis and pulmonary metastasis. 
Tissue samples.  Tissue samples of HNSCC were retrieved from the Surgical Pathology 
Registry of Hiroshima University Hospital from 1998 to 2004, after approval by the Ethical 
Committee of our institutions.  10 % buffered-formalin fixed and paraffin embedded tissues 
were used for immunohistochemical examination.  The histological grade and stage of tumor 
were classified according to the criteria of the Japan Society for Head and Neck Cancer.  
Fresh samples were taken from the neoplastic tissues and non-neoplastic tissues for RT-PCR 
analysis.
Immunohistochemical staining.  Immunohistochemical detection of Periostin in HNSCC 
cases was performed on 4.5 "m sections mounted on silicon-coated glass slides, using a 
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streptavidin-biotin peroxidase technique as described previously (11).  The expression of 
Periostin was graded as ++ (over 30 % of tumor cells showed strong or diffuse 
immunopositivity), + (10-30 % of tumor cells showed moderate or patchy immunopositivity) 
and - (less than 10 % of the tumor cells showed weak or focal immunopositivity or no staining).  
Three pathologists (Y.K., I.O., and T.T.) made all the assessments.  Possible correlation 
between variables of the analyzed tumor samples was tested for association by the Fisher's 
exact test.  A P value < 0.05 was required for significance.   
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Results 
Identification of Periostin as an overexpressed gene in a highly invasive HNSCC cell 
line.  We previously established a HNSCC cell line, MSCC-1, from lymph node metastasis 
(10).  Moreover, we isolated a highly invasive clone MSCC-Inv1 from MSCC-1 cells by using 
an in vitro invasion assay device (5).  In the present study, we compared the transcriptional 
profile of parent cells (MSCC-1) and a highly invasive clone (MSCC-Inv1) by microarray 
analysis in order to identify genes that differ in their expression (Fig.1A).  Several genes 
were selectively overexpressed in the highly invasive clone (Fig. 1A and Supporting Data 1).  
Among these genes, the most overexpressed gene was Periostin.  The finding of higher 
expression of Periostin in the highly invasive clone than the parent cells was confirmed by 
RT-PCR and immunoblotting (Fig. 1B and C).  For immunobloting, we generated a 
polyclonal Periostin antibody.  Moreover, MSCC-Inv1 cells secreted significant amounts of 
Periostin to media in comparison with MSCC-1 cells (Fig. 1D).  In the present study, 
Periostin was chosen to investigate its ability to promote the invasion of HNSCC. 
 
Overexpression of Periostin promotes invasion of HNSCC cells in vitro.  To 
demonstrate the involvement of Periostin in the invasion of HNSCC, we generated the 
Periostin overexpressing cells.  At first, we examined the Periostin mRNA in 5 HNSCC cell 
lines.  Among above 5 cell lines, only MSCC-1 and MSCC-Inv1 cells highly expressed 
Periostin (Fig. 2A).  Then, we transfected Periostin into HSC2 and HSC3 cells with slight 
expression of Periostin mRNA and obtained stable clones expressing Periostin (Fig. 2B).  In 
the following analyses, we used clone #2 of HSC2 and clone #3 of HSC3 cells, which showed 
Periostin overexpression.  Although Periostin overexpression did not promote the cell 
proliferation (Fig. 2C), it dramatically enhanced the invasiveness of both HSC2 and HSC3 
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cells (Fig. 2D2C).  Invasiveness was well correlated with ectopic expression levels of 
Periostin (Fig. 2C).  Moreover, treatment with recombinant Periostin protein also enhanced 
the invasiveness of HSC2 cells in a concentration dependent manner (Fig. 2E).  To confirm 
the correlation between Periostin and invasion, we reduced the expression of Periostin by 
small interference RNA (siRNA) treatment in MSCC-Inv1 cells (Fig. 2F2D).  Periostin siRNA 
treatment remarkably inhibited the invasion (Fig. 2G2D).  Overall, these results indicate that 
Periostin plays an important role in invasion of HNSCC. 
 
Periostin enhanced anchorage independent growth of HNSCC cells both in vitro and in 
vivo.  Similar to Periostin transfected HSC2 cells, treatment with recombinant Periostin 
protein also enhanced the invasiveness of HSC2 cells in a concentration dependent manner 
(Fig. 3A).  Periostin contains the four internal repeats of fasciclin I (FAS1) domain that 
represents an ancient cell adhesion domain common to plants and animals (13).  In 
mammals, there are four proteins containing FAS1 domains, specifically, two secretary 
proteins, Periostin and ßig-h3, and two membrane proteins, FEEL-1 and -2.  FAS1 of ßig-h3 
bears motifs interacting with integrins !3ß1 and !vß5 (14, 15) and mediates endothelial cell 
adhesion and migration via integrin !vß3 (16).  Similarly to ßig-h3, recombinant Periostin 
supports adhesion of ovarian epithelial cells that can be inhibited by monoclonal antibodies 
against !vß3 or !vß5 integrin, but not by anti-ß1 integrin antibody (17).  We also found that 
treatment of specific anti-!vß3 and anti-!vß5 integrin antibodies inhibited the adhesion of 
HSC2 cells to the culture wells precoated with Periostin, indicating that interference with the 
function of integrins has an effect on the ability of Periostin to mediate cell adhesion of 
HNSCC cells (Fig. 3A3B). 
                                                                       Kudo et al., 13        
 It has been suggested that alterations in cell?cell adhesion molecules, integrins or 
integrin-associated signaling molecules in cancer cells may be involved in anchorage-
independent growth (18).  Therefore, we hypothesize that Periostin may affect the 
anchorage-independent growth of HNSCC through the interaction with integrins.  To test this 
hypothesis, we examined the anchorage independent growth of Periostin overexpressing 
cells in vitro by using soft-agar colony formation assay.  In the following analysis, we used a 
clone #2 of HSC2 cells which showed higher invasiveness.  The Periostin overexpressing 
cells formed considerably larger colonies in the soft agar in comparison with control cells (Fig. 
3B3C).  In addition, the number of colonies with Periostin overexpressing cells was higher 
than those with control cells (Fig. 3C).  To determine the anchorage independent growth in 
vivo, Periostin overexpressing HNSCC cells were injected subcutaneously into nude mice.  
After 28 days, the growth characteristics of resulting tumors were analyzed.  Interestingly, 
transplantation of the Periostin overexpressing cells showed comparatively large tumor 
volume than that of the control cells (Fig. 3Da-c).  The volume of tumors derived from 
Periostin overexpressing cells was about sixteen fold higher than that of tumors from control 
cells (Fig. 3E3Dd).  Tumor volume was 187±57.1 and 11.4±10.4 in the Periostin 
overexpressed and control cells, respectively. 
 
Periostin overexpressing cells frequently metastasize to lymph nodes and lung 
through their aggressive invasiveness.  As demonstrated above experiments, Periostin 
enhanced invasion and anchorage independent growth of HNSCC cells.  To further evaluate 
if Periostin overexpression affects metastasis in vivo, we orthotopically implanted the 
Periostin overexpressing cells into the tongues of nude mice (Fig. 4A).  An orthotopic implant 
technique has been previously used to examine the lymphatic metastatic activity of human 
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HNSCC derived from different patients (19, 20).  After 2 weeks of implantation, mice were 
sacrificed.  Tumors were observed in the tongues of mice implanted with both Periostin 
overexpressing cells and control cells (Fig. 4Ba and Ca).  Strikingly, in mice implanted with 
Periostin overexpressing cells the tumors were larger than in mice implanted with control cells.  
Histologically, Periostin overexpressing tumors demonstrated a poorly differentiated 
phenotype characterized by a diffuse and trabecular growth pattern without keratinization.  In 
contrast, control tumors demonstrated characteristics consistent with a well differentiated 
phenotype with tumor islands with keratin pearl formation (Fig. 4Bb and Cb).  Moreover, 
Periostin overexpressing tumors showed remarkable invasiveness including destruction of 
mandibular bone and lymphocytic infiltration (Fig. 4Ca and Cc).  Interestingly, the Periostin 
overexpressing cells spontaneously metastasized to cervical lymph nodes (Fig. 4Cd) and lung 
(Fig. 4Ce).  Overall, 6 of 11 mice implanted with Periostin overexpressing cells showed 
metastasis to regional lymph nodes and/or lung, but no metastasis was observed in mice 
implanted with control cells (0 of 10) (Fig. 4D).  These findings suggest that Periostin 
overexpression may be involved in metastasis through aggressive invasiveness. 
 
Overexpression of Periostin is frequently found in HNSCC cases and associated with 
the invasiveness of HNSCC.  To determine if the upregulation of Periostin is a common 
feature of HNSCC in human subjects, we performed RT-PCR analysis on 3 normal tissues 
and 9 HNSCC samples.  As shown in Fig. 5Aa, the expression levels of Periostin mRNA in 
cancer tissues was higher than in normal tissues.  The average of Periostin expression 
levels (Periostin/Gapdh ratio) was 3-fold higher in tumors than normal tissues (Fig. 5B5Ab). 
 Next, we examined the expression of Periostin in 12 normal oral mucosae and 62 
HNSCC cases by immunohistochemistry.  HNSCC cells showed highly expression of 
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Periostin in comparison with normal oral mucosae (Fig. 5C 5Ba and b and Table 1).  In 62 
HNSCC cases, 26 (41.9 %) cases showed high expression of Periostin.  Then, we 
investigated the relationship between Periostin expression and the invasiveness in 62 102 
HNSCC cases.  For evaluation of invasiveness of HNSCC, we used the grading of mode of 
invasion (Grade 1 has a well defined borderline, Grade 2 has a less-marked borderline, 
Grade 3 has groups of cells and no distinct borderline, and Grade 4 has diffuse growth) as 
firstly described by Jacobsson et al. (21).  We defined two groups, low (Grade 1 and 2) and 
high (Grade 3 and 4).  Interestingly, higher expression of Periostin was significantly 
associated with the grading of mode of invasion (P<0.05) (Fig.5D 5Bc and d and Table 1).  
In particular, cancer cells at invasive front expressed Periostin at higher levels (Fig. 5E5Be).  
We also examined the association between Periostin expression and metastasis in 40 62 
HNSCC cases with available clinical information.  60 56.2 % of HNSCC cases with 
metastasis showed high expression of Periostin (Table 1). 
 To further evaluate the expression of Periostin in patients with HNSCC we compared 
the expression in a previously published microarray dataset of 41 HNSCC patients and 13 
normal controls (9).  Similar to our data, Periostin was expressed at higher levels in HNSCC 
tissues, in comparison with normal oral mucosal tissues (Fig. 5F5C).  Moreover, HNSCC 
cases with angiolymphatic invasion showed higher expression of Periostin (Fig. 5F5C).  To 
further explore the genes that are coordinately expressed with Periostin in HNSCC tumors, 
we performed a similarity search using a Pearson correlation metric as implemented in 
tGeneData Analyst Pro 1.0 software.  The expression of selected genes demonstrating the 
highest coordinate expression with periostin in normal oral mucosal tissue and HNSCC 
tissues was then visualized by hierarchical clustering (Fig. 5G5D).  FAP, SULF1, COL5A2, 
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COL3A1, COL10A1, COL4A1, FN1 and INHBA were well correlated with Periostin expression 
(Fig. 5G 5D and Supplemental data 2). 
 
Discussion 
It is believed that neoplasms contain a variety of subpopulations of cells with differing 
metastatic potential, and the presence of highly metastatic clones may exist within a primary 
tumor (4).  Recent data demonstrate that reinjection of metastatic cell populations can lead 
to enrichment in the metastatic phenotype by work on experimental metastasis with cancer 
cell lines (22-25).  Further, metastasis related genes were identified by comparing the gene 
expression profiles between parent and metastatic cell populations using microarray analysis 
(22-25).  We previously established HNSCC cell line from metastatic cervical lymph node of 
HNSCC and then isolated highly invasive clones from this cell line by in vitro invasion assay 
(5, 10).  By using these cell lines, we demonstrated that methylation of E-cadherin and 
degradation of ß-catenin were involved in the invasion of HNSCC through the loss of cell-cell 
adhesion (5).  Thus, we previously could obtain the highly invasive phenotype by isolation of 
cell populations using an in vitro invasion assay.  Therefore, we thought that comparing the 
gene expression profile of the parent and highly invasive clone could be a good approach to 
identify genes that influence the invasion of HNSCC.  Here, we identified several genes, 
which encode secretary or cell surface proteins implicated in invasion, cell adhesion, 
angiogenesis and growth factor as candidate genes for the invasion of HNSCC by comparing 
the gene expression profiles between parent HNSCC cells and a highly invasive clone using 
microarray analysis.  Among these genes, Periostin was found to be the most highly 
expressed gene in invasive HNSCC cells.  As expected, overexpression of Periostin 
dramatically promoted the invasion of HNSCC cells in vitro.  Moreover, invasive phenotype 
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was abolished by Periostin siRNA treatment.  These observations strongly indicate that 
Periostin plays an important role in the invasion of HNSCC.  In addition, we found that 
Periostin overexpression did not promote proliferation, but growth in soft agar and in vivo 
growth as tumor xenografts, demonstrating that Periostin enhances anchorage independent 
growth of HNSCC cells. 
 Periostin contains an N-terminal secretory signal peptide, followed by a cysteine-rich 
domain, four internal homologous repeats, and a C-terminal hydrophilic domain.  The four 
internal repeats region of Periostin shares a homology with the axon guidance protein FAS1 
containing sequences that allows binding of integrins and glycosaminoglycans in vivo (26).  
FAS1 domains of ßig-h3, which shares a significant structural homology with Periostin, bear 
motifs interacting with integrins !3ß1 and !vß5 (14, 15) and mediate endothelial cell 
adhesion and migration via integrin !vß3 (16).  Similarly to ßig-h3, we found that interference 
with the function of integrins by specific anti-!vß3 and anti-!vß5 integrin antibodies had an 
effect on the ability of Periostin to mediate cell adhesion in HNSCC cells.  Taken together, 
these data strongly suggest that FAS1 domain of Periostin binds to integrins.  It is well 
known that integrin mediates cell-extracellular matrix (ECM) interaction and that integrin-
mediated adhesion regulates a variety of intracellular events (27).  Therefore, we 
hypothesize that Periostin-integrin interaction may inhibit the ECM-integrin interaction and 
trigger the intracellular signaling and activation of certain genes that are involved in invasion 
and anchorage independent growth of HNSCC.  This hypothesis is supported by recent 
report that Periostin activated the Akt/PKB pathway via the !vß3 integrin to promote cellular 
survival in colon cancer (28).  We suggest that overexpression of Periostin may confer on 
HNSCC cells the ability to survive in the absence of anchorage by inhibiting anoikis-related 
apoptotic pathways, thus allowing Periostin overexpressing HSC2 cells to form colonies in 
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soft agar and tumors in nude mice.  However, in order to clarify the underlying mechanism of 
invasion and anchorage independent growth by Periostin, further studies are required. 
 As mentioned above, Periostin promoted invasion and anchorage independent growth in 
HNSCC cells.  These striking phenotypes seem to be an important for cancer metastasis.  
Interestingly, Periostin overexpression dramatically induced metastasis to lymph nodes and to 
the lung in an orthotopic implant model of HNSCC, demonstrating spontaneous metastasis 
from tongue.  This orthotopic implant model of HNSCC seems clinically relevant because its 
tumor progression containing metastasis mimic the clinical scenario.  Moreover, Periostin 
overexpressing tumors showed forming a larger tumor mass and remarkable invasiveness 
including destruction of mandibular bone and lymphatic infiltration.  Therefore, we suggest 
that aggressive invasiveness and anchorage independent growth by Periostin overexpression 
may consequently lead to metastasis.  To confirm the role of Periostin in metastasis as 
described above, we would like to examine the effect of Periostin siRNA in vivo in the future.  
Indeed, immunohistochemical analysis revealed that Periostin expression was well 
associated with the pattern of invasion and lymph node metastasis in HNSCC cases.  
Moreover, 56.2 % of HNSCC cases with metastasis showed higher expression of Periostin, 
but we could not find statistical significance between Periostin expression and metastasis.  In 
near future, we will examine the correlation between Periostin expression and metastasis in a 
large number of HNSCC cases.  Interestingly, Bao et al. also demonstrated that a colon 
cancer cell line with low metastatic potential engineered to overexpress Periostin displayed a 
striking phenotype of greatly accelerated tumor metastatic growth as xenografts in the animal 
model system of metastasis (28).  Importantly, higher expression of Periostin was frequently 
observed in HNSCC tissues in comparison with normal tissues.  By evaluation of Periostin 
expression in HNSCC patients, a strong correlation of Periostin expression with FAP, SULF1, 
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COL5A2, COL3A1, COL10A1, COL4A1, FN and INHBA was observed.  Although we have to 
confirm this correlation, this finding gives an imagination that Periostin expression appears to 
be correlated with a stromal reaction likely related to invasion and metastasis.  In addition, 
previous studies have shown that Periostin expression is up-regulated in various types of 
tumor including HNSCC (29), colon (28, 30), breast (31), lung (32) and ovarian cancer (17).  
Taken together, highly expression of Periostin may be a common event of tumor development 
in various types of cancer and can be a useful marker to predict its malignancy.  In fact, 
serum levels of Periostin were elevated in patients with breast cancer, non-small cell lung 
cancer and thymoma (33-35).  Therefore, we will examine the detection of Periostin in saliva 
and blood from the patients with HNSCC in the future.  In conclusion, our studies have 
revealed a critical role of Periostin for invasion and anchorage independent growth in the 
metastatic process.  These findings provide new and important information on the 
progression of HNSCC.  The finding that Periostin influences metastatic potential 
demonstrated in this study raises the possibility that it could be used as a molecular target in 
anti-metastasis therapy of HNSCC patients. 
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Figure legends 
Figure 1. Periostin is identified as an invasion related gene in HNSCC.  (A) Schematic 
representation of the isolation process of highly invasive clone.  Highly invasive clone 
(MSCC-Inv1) was isolated from parent cells (MSCC-1) by in vitro invasion assay.  The 
transcriptional profile of MSCC-1 cells and MSCC-Inv1 cells were compared by microarray 
analysis.  Highly expressed genes in the highly invasive clone are listed.  Among these 
genes, the mostly overexpressed gene in the highly invasive clone is Periostin (redbold).  (B) 
Confirmation of higher expression of Periostin mRNA in the highly invasive clone by RT-PCR.  
Amplification was performed for 30 cycles.  (C) Confirmation of higher expression of 
Periostin protein in the highly invasive clone by Western blot analysis.  ß-actin expression 
was used as a loading control.  (D) The production of Periostin by MSCC-1 and MSCC-Inv1 
cells.  The production of Periostin was examined by Western blot analysis with conditioned 
culture media. 
 
Figure 2. Periostin promotes the invasion of HNSCC cells.  (A) Expression of Periostin 
mRNA in HNSCC cell lines.  Expression of Periostin mRNA in HSC2, HSC3, Ca9-22, and 
MSCC-1 and MSCC-Inv1 cells by RT-PCR was examined.  Amplification was performed for 
35 cycles.  (B) Generation of Periostin overexpressing cells.  HSC2 and HSC3 cells were 
engineered to overexpress Periostin by transfection with pcDNA3.1-His tagged Periostin.  
We obtained each 4 stable clones expressing Periostin.  Ectopic expression of Periostin was 
examined by immunobloting with anti-His antibody.  The whole lysates from all samples were 
blotted with ß-actin for loading control.  (C) Cell proliferation (upper panel) and invasion 
(lower panel) of Periostin overexpressing HNSCC cells.  Cells were plated on 24 well plates 
and trypsinized cells were counted by Cell Counter at 0, 2 and 4 day.  (D) Invasion of 
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Periostin overexpressing HNSCC cells.  The invasiveness of the cells was determined by in 
vitro invasion assay.  (E) Treatment with Recombinant Periostin enhanced invasiveness in 
HNSCC.  Recombinant Periostin protein (0, 1 and 10 mg/ml) was treated in HSC2 cells.  
The invasiveness of the cells was determined by in vitro invasion assay.  (FD) Knockdown of 
Periostin in MSCC-Inv1 cells.  Periostin siRNA were transfected.  Upper panel shows that 
Tthe effectiveness at knockdown the expression of Periostin was validated at the mRNA by 
RT-PCR and at the protein level by immunobloting with anti-Periostin antibody.  (G) Lower 
panel shows that Kknockdown of Periostin inhibits the invasiveness of HNSCC cells.  The 
invasiveness of the cells was determined by in vitro invasion assay. 
 
Figure 3. Periostin is involved in the anchorage independent growth of HNSCC in vitro and in 
vivo.  (A) Treatment with Recombinant Periostin enhanced invasiveness in HNSCC.  
Recombinant Periostin protein (0, 1 and 10 mg/ml) was treated in HSC2 cells.  The 
invasiveness of the cells was determined by in vitro invasion assay.  (B) Interaction between 
Periostin and Integrin in HNSCC cells.  HSC2 cells (3 x 104 cells/well) were cultured in a 96-
well plate precoated with 10 "g/ml of recombinant Periostin in the presence of anti-!vß3 or 
anti-!vß5 integrin antibody (10 "g/ml) for 1 hour.  Non-coated wells were used as a control.  
Adhesive cells were counted after washing.  (BC) Colony formation of Periostin 
overexpressing HNSCC cells in soft agar.  After 3 weeks, colonies were photographed.  
Upper panel shows Rrepresentative photographs of colonies are shown.  (C) Lower panel 
shows Nnumber of colonies of Periostin overexpressing HNSCC cells.  The colonies under a 
phase contrast microscope were counted at x10 magnification.  We assayed twice and 
randomly selected 5 fields were counted for each assay.  (D) Representative results showing 
the tumor growth of xenografts in immunocompromised mice.  Periostin overexpressing and 
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control HSC2 cells (1 # 107 cells) were individually injected subcutaneously into 2 sites in 
each 5 nude mice.  After 1 month, the growth characteristics of the resulting tumors were 
analyzed.  (a) Representative photographs of tumors.  (b) Higher magnification of 
photographs of tumors.  (c) Gross appearance of the tumor masses.  (Ed) The volume of 
tumors.  Tumor length (L) and width (W) were measured and tumor volume was calculated 
by the formula of (L x W2)/2. 
 
Figure 4. Periostin promotes metastasis of HNSCC mediated by aggressive invasiveness in 
vivo.  (A) Schema of orthotopic implantation of HNSCC cells with or without Periostin 
overexpression.  Periostin overexpressing and control cells (5 # 105 cells) were orthotopically 
implanted into tongue of nude mice.  After 2 weeks, tongue tumors, cervical lymph nodes 
and lungs were dissected.  (B) Representative hematoxyline and eosin-stained images of 
histopathological sections from mice injected with control cells.  (a) Histology of tumor mass 
in the tongue.  (b) High power of (a).  Tumor mass is enclosed with dotted line.  Original 
magnifications: x5 (a); x25 (b).  (C) Representative hematoxyline and eosin-stained images 
of histopathological sections from mice injected with Periostin overexpressing cells.  (a) 
Histology of tumor mass in the tongue.  (b) High power of (a).  (c) Histology of invading 
tumor in lymphatics.  (d) Histology of lymph node metastasis.  (e) Histology of lung 
metastasis.  Arrow indicates invaded tumor (c) and metastasized tumor (d and e).  Original 
magnifications: x5 (a); x25 (b-e).  (D) Summary of the metastasis of Periostin overexpressing 
and control cells injected mice. 
 
Figure 5. Higher expression of Periostin is frequently observed in HNSCC.  (A) (a) 
Expression of Periostin mRNA in 9 HNSCC tissues (T) and 3 normal tissues (N) by RT-PCR.  
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Graph shows the Periostin/GAPDH ratios which was measured by densitometry.  (Bb) The 
average of Periostin/GAPDH ratios.  The average of Periostin/GAPDH ratios in HNSCC 
cases (T) and in normal tissues (N) is 1.86±0.40 and 0.51±0.22, respectively.  (CB) 
Immunohistochemical analysis of Periostin.  Expression of Periostin was examined by 
immunohistochemistry in HNSCC (Cancer) (a) and normal oral mucosae (Normal) (b).  (D) 
To know the Ccorrelation between Periostin expression and Invasiveness invasiveness of 
HNSCC, we.  To evaluated the invasiveness of HNSCC by using invasion grading, , we 
defined two groups as as low (Grade 1 and 2) and high (Grade 3 and 4)???Representative 
cases of low (c) and high (d) groups are shown.  (E) Periostin expression in invasive front of 
HNSCC.  Representative case of higher expression of Periostin in invasive front is shown (e).  
(FC) Clustering of HNSCC samples to demonstrate relative expression of Periostin.  Total 
RNA from 41 primary HNSCC and 13 normal tissues was labeled and hybridized to Affymetrix 
U133A Gene Chips as previously reported (9).  The average of signal intensity of Periostin in 
41 HNSCC and 13 normal tissues in microarray analysis.  Left graph shows signal intensity 
of Periostin in normal and HNSCC tissues.  Right graph shows signal intensity of Periostin in 
HNSCC cases with or without angiolymphatic invasion.  The average of signal intensity of 
Periostin is shown at the bottom of the graph.  (GD) Clustering of 41 HNSCC and 13 normal 
tissues to demonstrate relative expression of Periostin.  We analyzed by hierarchical 
clustering using a filtered set of 6800 variably expressed genes.  The gene cluster that 
includes Periostin is highlighted in blue in the horizontal dendrogram. 
 
Supplemental data 
Microsoft Excel file 1. Raw expression data of microarray analysis between parent cells and 
highly invasive clone. 
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Microsoft Excel file 2. Raw data of correlation analysis for Periostin. 
  
 
Table 1. Periostin expression in normal oral mucosae and HNSCC and correlation with 
invasion and metastasis. 
 
 
 
 
 
 
 
 
 
 
*The expression of Periostin was graded as ++ (over 30 % of tumor cells showed strong or diffuse 
immunopositivity), + (10-30 % of tumor cells showed moderate or patchy immunopositivity) and - (less than 10 % 
of the tumor cells showed weak or focal immunopositivity or no staining). 
No. of cases 
Periostin expression (%)* 
-            ? +         ?   ++ 
Normal 
 
HNSCC 
12 
 
102 
 9 (75.0) 
 
20 (19.6) 
3 (25.0) 
 
39 (38.2) 
0 (0) 
 
43 (42.2) 
Invasion grading 
Low 
 
High 
22 
 
80 
9 (40.9) 
 
11 (13.75) 
8 (36.4) 
 
31 (38.75) 
5 (22.7) 
 
38 (47.5) 
Metastasis 
Negative 
 
Positive 
30 
 
32 
5 (16.7) 
 
3 (9.4) 
14 (46.7) 
 
11 (34.4) 
11 (36.6) 
 
18 (56.2) 
P value 
0.01 
0.28 
0.0001 
GAPDH
Periostin
M
S
C
C
-1
M
S
C
C
-I
n
v
1
M
S
C
C
-1
M
S
C
C
-I
n
v
1
ß-actin
Periostin
M
S
C
C
-1
M
S
C
C
-I
n
v
1
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Parent oral cancer cell 
(MSCC-1)
Isolation
Highly invasive clone 
(MSCC-Inv1)
Microarray analysis
MSCC-1 vs MSCC-Inv1
Probe_Name Ratio Description
NM_006475.1 65.175345 OSTEOBLAST SPECIFIC FACTOR 2 (FASCICLIN I-LIKE) (OSF-2/Periostin)
NM_003641.1 18.556444 INTERFERON INDUCED TRANSMEMBRANE PROTEIN 1 (9-27) (IFITM1)
NM_032642.1 18.173555 WINGLESS-TYPE MMTV INTEGRATION SITE FAMILY, MEMBER 5B (WNT5B), TRANSCRIPT VARIANT 1
NM_001387.1 16.965932 DIHYDROPYRIMIDINASE-LIKE 3 (DPYSL3)
AA810805 13.177289 603639245F1 HOMO SAPIENS CDNA, 5' END
NM_005397.1 12.508605 PODOCALYXIN-LIKE (PODXL)
X16323 11.012348 MRNA FOR HEPATOCYTE GROWTH FACTOR (HGF)
NM_007036.2 9.4544153 ENDOTHELIAL CELL-SPECIFIC MOLECULE 1 (ESM1)
NM_002575.1 9.446 SERINE (OR CYSTEINE) PROTEINASE INHIBITOR, CLADE B (OVALBUMIN), MEMBER 2 (SERPINB2)
NM_000055.1 8.7671114 BUTYRYLCHOLINESTERASE (BCHE)
NM_001920.1 8.5095798 DECORIN (DCN)
NM_006528.1 7.0713753 TISSUE FACTOR PATHWAY INHIBITOR 2 (TFPI2)
AK023450 6.958723 CAPILLARY MORPHOGENESIS PROTEIN 2 (CMG2)
NM_007363.2 6.6625375 NON-POU-DOMAIN-CONTAINING, OCTAMER-BINDING (NONO)
NM_032495.1 6.2201358 HYPOTHETICAL PROTEIN SMAP31 (SMAP31)
NM_001257.1 6.0081838 CADHERIN 13, H-CADHERIN (HEART) (CDH13)
BC009269 5.8917143 MRNA FOR PUTATIVE OXIDOREDUCTASE
NM_002192.1 5.5939091 INHIBIN, BETA A (ACTIVIN A, ACTIVIN AB ALPHA POLYPEPTIDE) (INHBA)
NM_000627.1 5.4214464 LATENT TRANSFORMING GROWTH FACTOR BETA BINDING PROTEIN 1 (LTBP1)




